HCM

HUTCHMED (China) Limited discovers, develops, and commercializes targeted oncology and immunology therapeutics for global markets. Headquartered in Hong Kong with operations across China, the United States, and Europe, the company focuses on bringing innovative medicines to cancer patients through both proprietary R&D and strategic partnerships. Its commercial portfolio includes ELUNATE (fruquintinib), a treatment for metastatic colorectal cancer approved in China and marketed as FRUZAQLA in the U.S. following FDA approval in 2023, and SULANDA (sulfatinib) for neuroendocrine tumors. HUTCHMED operates through two primary business segments: its oncology/immunology platform developing small molecule therapeutics targeting cancer hallmarks, and its other ventures segment including HUTCHMED Healthcare Holdings and Nutrition Science Partners. The company maintains a robust pipeline with multiple drug candidates in various clinical stages, including sovleplenib, tazemetostat, and several other targeted therapies. HUTCHMED has established significant collaborations with major pharmaceutical companies including AstraZeneca and Takeda Pharmaceutical, enabling broader global reach for its innovations. The company employs approximately 5,000 people and operates state-of-the-art manufacturing and R&D facilities in Shanghai and Suzhou. Its integrated business model spans drug discovery through commercialization, positioning it as a leading China-based biopharmaceutical company with expanding international presence. HUTCHMED trades on the NASDAQ, London Stock Exchange, and Hong Kong Stock Exchange.